Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Item

http://www.wikidata.org/entity/Q39013620

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

@en

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

@nl

type

Item

label

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

@en

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

@nl

prefLabel

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

@en

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

@nl

P1476

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

@en

P2093

A Badros

http://www.w3.org/2001/XMLSchema#string

A Larocca

http://www.w3.org/2001/XMLSchema#string

A Mahindra

http://www.w3.org/2001/XMLSchema#string

A Mazumder

http://www.w3.org/2001/XMLSchema#string

A Nouel

http://www.w3.org/2001/XMLSchema#string

A Palumbo

http://www.w3.org/2001/XMLSchema#string

A Reiman

http://www.w3.org/2001/XMLSchema#string

B G M Durie

http://www.w3.org/2001/XMLSchema#string

B M Weiss

http://www.w3.org/2001/XMLSchema#string

E R Serra

http://www.w3.org/2001/XMLSchema#string

P2860

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

P304

228-245

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDW606

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

S. Vincent Rajkumar

Robert A Kyle

International Myeloma Working Group

P577

2016-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27864218

http://www.w3.org/2001/XMLSchema#string